Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care.

Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care.

The commonest manifestations of cardiovascular disease, namely coronary heart disease (CHD) and stroke, represent the two most common causes of death in the world today. Furthermore, cardiovascular diseases have the highest healthcare utilisation costs in most countries. Both primary and secondary p...

Szczegółowa specyfikacja

Opis bibliograficzny
1. autor:	Hobbs, F
Format:	Journal article
Język:	English
Wydane:	2003

Podobne zapisy

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
od: article Editorial
Wydane: (2020-09-01)

Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up.
od: Hobbs, R, i wsp.
Wydane: (2005)

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
od: Alberto J Lorenzatti, i wsp.
Wydane: (2020-02-01)

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
od: Mach, F, i wsp.
Wydane: (2019)

Biochemical effects of statins on lipid parameters among newly diagnosed dyslipidaemia subjects in primary care
od: Meor Anuar Shuhaili, Meor Fairuz Rizal, i wsp.
Wydane: (2018)

Seasonal variation lipid levels in the patients with dyslipidaemia
od: I V Radysh, i wsp.
Wydane: (2009-12-01)

Cardiovascular risk management in primary care.
od: Hobbs, F
Wydane: (2002)

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk
od: Francois Mach, i wsp.
Wydane: (2020-06-01)

Dyslipidaemia—Genotype Interactions with Nutrient Intake and Cerebro-Cardiovascular Disease
od: Sung-Bum Lee, i wsp.
Wydane: (2022-07-01)

Current insights on dyslipidaemia management for prevention of atherosclerotic cardiovascular disease: a malaysian perspective
od: Wan Ahmad, Wan Azman, i wsp.
Wydane: (2023)

Dyslipidaemia in patients with chronic kidney disease – a neglected cardiovascular risk factor
od: M R Essop, i wsp.
Wydane: (2023-11-01)

Managing dyslipidaemia in patients with chronic kidney disease
od: Ashwani Mehta
Wydane: (2024-03-01)

Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
od: Alicja E. Grzegorzewska, i wsp.
Wydane: (2021-03-01)

Serum zinc levels in diabetic patients with and without dyslipidaemia and cardiovascular diseases
od: Lakmal Jayaweera, i wsp.
Wydane: (2020-08-01)

Role of dyslipidaemia and lipid peroxidation in pregnancy induced hypertension
od: Saxena S, i wsp.
Wydane: (2015-07-01)

New concepts in the management of dyslipidaemia
od: Baris Gencer, i wsp.
Wydane: (2016-11-01)

Managing dyslipidaemia in young adults
od: Jamshed J. Dalal, i wsp.
Wydane: (2024-03-01)

Role of statins in the management of dyslipidaemia
od: Saumitra Ray
Wydane: (2024-03-01)

The changing paradigm of dyslipidaemia management
od: Ruvan Ekanayaka
Wydane: (2017-04-01)

Update on the Management of Diabetic Dyslipidaemia
od: Iciar Martín-Timón, i wsp.
Wydane: (2018-11-01)

The scale of heart failure: diagnosis and management issues for primary care.
od: Hobbs, F
Wydane: (1999)

Primary prevention of cardiovascular disease: managing hypertension and hyperlipidaemia.
od: Hobbs, F
Wydane: (2004)

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
od: Maciej Banach, i wsp.
Wydane: (2022-09-01)

Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
od: Alberto Zambon
Wydane: (2020-04-01)

The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia
od: Di Liu, i wsp.
Wydane: (2018-08-01)

Emerging Strategies for the Management of Atherogenic Dyslipidaemia
od: Anandita Agarwala, i wsp.
Wydane: (2020-02-01)

Established and Emerging Approaches for the Management of Dyslipidaemia
od: Giuseppe Danilo Norata
Wydane: (2012-01-01)

Secondary dyslipidaemia
od: D.J. Blom
Wydane: (2011-07-01)

Diabetic dyslipidaemia
od: Subashini C. Thambiah, i wsp.
Wydane: (2021-08-01)

Obstructive Sleep Apnoea and Lipid Metabolism: The Summary of Evidence and Future Perspectives in the Pathophysiology of OSA-Associated Dyslipidaemia
od: Martina Meszaros, i wsp.
Wydane: (2022-10-01)

Lipid management in cardiovascular disease prevention guidelines: strategies and tactics for implementation.
od: Erhardt, L, i wsp.
Wydane: (2008)

Effectiveness of an audit programme for dyslipidaemia management in a primary care setting in Macau: a quality improvement study
od: In Wong, i wsp.
Wydane: (2020-01-01)

Optimisation of lipids for prevention of cardiovascular disease in a primary care
od: Smita Bakhai, i wsp.
Wydane: (2018-07-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
od: Tiny Nair
Wydane: (2024-03-01)

2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS
od: Alberico L. Catapano, i wsp.
Wydane: (2017-06-01)

Trends in prevalence of dyslipidaemias and the risk of mortality in Lithuanian urban population aged 45-64 in relation to the presence of the dyslipidaemias and the other cardiovascular risk factors.
od: Dalia Luksiene, i wsp.
Wydane: (2014-01-01)

Dyslipidaemia and inflammatory markers as the risk predictors for cardiovascular disease in newly diagnosed premenopausal hypothyroid women
od: Balamurugan Vaideki, i wsp.
Wydane: (2023-01-01)

Dyslipidaemia in endocrine disorders
od: Kalyani Sridharan, i wsp.
Wydane: (2024-03-01)

Treatment of Dyslipidaemia in Children
od: Riccardo Fiorentino, i wsp.
Wydane: (2021-08-01)

Dyslipidaemia in Sri Lanka
od: Anne Thushara Matthias, i wsp.
Wydane: (2022-01-01)